

PRECEPTORSHIP PROGRAMME

Metastatic Bladder and Kidney Cancer

Multidisciplinary management,
standards of care, therapeutic targets
and future perspectives

**ESMO VIRTUAL
PRECEPTORSHIP**

27-28 NOVEMBER 2020

Co-Chairs

Aristotelis Bamias, Greece
Camillo Porta, Italy

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME METASTATIC BLADDER AND KIDNEY CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

27-28 November 2020

CO-CHAIRS: Aristotelis Bamias, Greece
Camillo Porta, Italy

SPEAKERS: Patrizia Giannatempo, Italy
Viktor Grünwald, Germany
Maria Carmen Mir Maresma, Spain
Holger Moch, Switzerland
Manuela Schmidinger, Austria

LEARNING OBJECTIVES

- To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer
- To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer
- To learn about advances in treatment and novel targets in bladder and kidney cancer

ACCREDITATION

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For the future details please refer to esmo.org

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



ALL timings are to be considered CET (Central European Time)

Friday, 27 November 2020

14:00-14:05 5'	Opening and welcome	
5'	Welcome from ESMO - Objectives and scientific introduction	Aristotelis Bamias, GR
14:05-14:35 30'	SESSION 1 - Pathology and molecular pathology	Chair/Moderator: Aristotelis Bamias, GR
10'	Bladder cancer	Holger Moch, CH
10'	Kidney cancer	Holger Moch, CH
10'	Discussion	Faculty
14:35-16:05 90'	SESSION 2 – How to treat metastatic bladder cancer	Chair/Moderator: Aristotelis Bamias, GR
15'	1 st line mUC management	Aristotelis Bamias, GR
15'	2 nd line and beyond: the art and science of sequencing in mUC	Patrizia Giannatempo, IT
15'	Discussion	Faculty
45'	Participants clinical case discussion (3x15')	Faculty
16:05-16:20	Break	
16:20-17:20 60'	SESSION 3 – How to treat metastatic renal cell cancer (RCC)	Chair/Moderator: Aristotelis Bamias, GR
10'	Surgery	Maria Carmen Mir Maresma, ES
15'	1 st line treatment for clear-cell mRCC	Camillo Porta, IT
15'	2 nd line treatment for cc mRCC and sequencing of therapies	Viktor Grünwald, DE
10'	Treatment for non-clear-cell mRCC	Manuela Schmidinger, AT
10'	Discussion	Faculty

Saturday, 28 November 2020

14:00-14:45 45'	SESSION 4 – Debate of the day	Chair/Moderator: Camillo Porta, IT
30'	Should VEGFR TKI + CPI combination be the standard 1 st line systemic therapy for all metastatic RCC patients? YES/NO	YES – Viktor Grünwald, DE NO – Manuela Schmidinger, AT
15'	Discussion	Faculty

14:45 -15:30 45'	SESSION 5 – Personalized therapy in metastatic bladder cancer and RCC	Chair/Moderator: Camillo Porta, IT
15'	Bladder cancer	Aristotelis Bamias, GR
15'	RCC	Camillo Porta, IT
15'	Discussion	Faculty
15:30-15:45	Break	
15:45-17:25 100'	SESSION 6 - Side effects	Chair/Moderator: Camillo Porta, IT
10'	Chemotherapy	Patrizia Giannatempo, IT
15'	Tyrosine Kinase Inhibitors and mTOR Inhibitors in RCC	Viktor Grünwald, DE
15'	Immunotherapy	Manuela Schmidinger, AT
15'	Discussion	Faculty
45'	Participants clinical case discussion (3x15')	Faculty
17:25-17:30 5'	Conclusion and farewell	Camillo Porta, IT

Note: Each 15-minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion